Receptors are the specific cellular structures with which drugs and hormones first interact (LEFKOWITZ, 1976a). They may be located at the cell surface or within the cell and they perform two important functions. They first bind drug or hormone molecules through some complementarity of chemical structure between the receptor and the drug or hormone. If an agonist occupies the receptor, a biological process such as enzyme activation, ion influx or effiux across membranes, or production or utilization of energy is then triggered. If an antagonist binds to the receptor, it does not cause a measurable response, but rather blocks the effects of the agonist or hormone.Thirty years ago, AHLQUIST first divided adrenoceptors into iX-and p-subtypes, based on the relative potencies of a series of adrenergic agonists (catecholamines) in stimulating various physiologic responses (AHLQUIST, 1948(AHLQUIST, , 1966. One set of responses (vasoconstriction of the viscera and the gut, excitation of the uterus and ureters, contraction of the nictitating membrane, dilation of the pupil, and inhibition of the gut) was very sensitive to epinephrine (1) and norepinephrine (2), whereas isoproterenol (3) was very weak (sequence I). A second set of responses (vasodilation, inhibi-(2) tion of uterine contractility, and myocardial stimulation) was most sensitive to isoproterenol and epinephrine with norepinephrine considerably weaker (sequence II). The responses following sequence I were considered to be initiated through iX-receptors and those following sequence II were acting through p-receptors. The iX-receptor was associated with most, but not all, excitatory functions. The p-receptor was associated with most inhibitory functions.AHLQUIST also showed that the drugs ergotoxine [a 1: 1: I-mixture of (4 a), (4 b), and (4c)], dibenamine (5), and tolazoline (6) blocked the physiologic responses produced by stimulation of the iX-receptor.At the time AHLQUIST made the proposal, there were no p-receptor antagonists, and the dual adrenoceptor hypothesis was not widely accepted. In 1958, dichloroisoproterenol (DCI, 7) was des~ribed by POWELL and SLATER as an antagonist of the inhibitory properties of epinephrine. MORAN and PERKINS (1958) pointed out that this agent was a specific and selective antagonist of the cardiac ionotropic and chronotro-L. Szekeres (ed.), Adrenergic Activators and Inhibitors